ProKidney (PROK)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	108.09 mm	108.09 mm	108.09 mm	108.09 mm	108.09 mm	108.09 mm
Cash burn (monthly)	35.47 mm	6.94 mm	16.32 mm	13.03 mm	9.75 mm	10.63 mm
Cash used (since last report)	155.91 mm	30.51 mm	71.75 mm	57.25 mm	42.84 mm	46.72 mm
Cash remaining	-47.82 mm	77.58 mm	36.34 mm	50.84 mm	65.25 mm	61.37 mm
Runway (months of cash)	-1.3	11.2	2.2	3.9	6.7	5.8

Beta Read what these cash burn values mean

Financial data from ProKidney earnings reports.

Institutional ownership, Q3 2024

PROK institutional ownership history Ownership history

79.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	78	73	+6.8%
Opened positions	16	21	-23.8%
Closed positions	11	5	+120.0%
Increased positions	35	28	+25.0%
Reduced positions	8	13	-38.5%

13F shares	Current	Prev Q	Change
Total value	94.43 bn	99.13 bn	-4.8%
Total shares	231.96 mm	222.98 mm	+4.0%
Total puts	126.90 k	117.60 k	+7.9%
Total calls	505.00 k	644.00 k	-21.6%
Total put/call ratio	0.3	0.2	+37.6%

Largest owners	Shares	Value	Change
Tolerantia	111.26 mm	$330.44 mm	0.0%
Carso, S.A. de C.V. Inversora	71.56 mm	$173.18 mm	0.0%
MS Morgan Stanley	14.27 mm	$27.40 bn	-1.2%
Suvretta Capital Management	12.34 mm	$23.70 bn	+32.1%
BlackRock	6.41 mm	$12.31 bn	NEW
Vanguard	5.22 mm	$10.01 bn	+31.2%
Geode Capital Management	2.20 mm	$4.23 bn	+102.0%
Bleichroeder	1.85 mm	$3.54 bn	-29.4%
STT State Street	1.43 mm	$2.74 bn	+16.2%
Brown University	1.00 mm	$1.92 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
BlackRock	6.41 mm	+6.41 mm	NEW
BLK BlackRock	0.00	-3.66 mm	EXIT
Suvretta Capital Management	12.34 mm	+3.00 mm	+32.1%
Vanguard	5.22 mm	+1.24 mm	+31.2%
Geode Capital Management	2.20 mm	+1.11 mm	+102.0%
Bleichroeder	1.85 mm	-767.50 k	-29.4%
NTRS Northern Trust	829.70 k	+486.69 k	+141.9%
Charles Schwab Investment Management	749.72 k	+450.55 k	+150.6%
STT State Street	1.43 mm	+198.84 k	+16.2%
MS Morgan Stanley	14.27 mm	-177.96 k	-1.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PROK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
4 Feb 25	Pereira Brian JG	Class A Ordinary Shares	Conversion	Acquire C	Yes	No	675,234	675,234
4 Feb 25	Pereira Brian JG	Class A Ordinary Shares	Conversion	Acquire C	No	No	81,928	81,928
4 Feb 25	Pereira Brian JG	Common Units in ProKidney LP Class A Ordinary Shares	Conversion	Dispose C	Yes	No	675,234	675,235
4 Feb 25	Pereira Brian JG	Class B Ordinary Shares Class A Ordinary Shares	Conversion	Dispose C	Yes	No	675,234	675,235
4 Feb 25	Pereira Brian JG	Common Units in ProKidney LP Class A Ordinary Shares	Conversion	Dispose C	No	No	81,928	81,929
4 Feb 25	Pereira Brian JG	Class B Ordinary Shares Class A Ordinary Shares	Conversion	Dispose C	No	No	81,928	81,929
4 Feb 25	Legorreta Pablo G.	Class A Ordinary Shares	Other	Dispose J	Yes	No	532,535	22,617,909
4 Feb 25	Legorreta Pablo G.	Class A Ordinary Shares	Conversion	Acquire C	Yes	No	532,535	23,150,444
4 Feb 25	Legorreta Pablo G.	Common Units in ProKidney LP Class A Ordinary Shares	Conversion	Dispose C	Yes	No	532,535	88,107,426
4 Feb 25	Legorreta Pablo G.	Class B Ordinary Shares Class A Ordinary Shares	Conversion	Dispose C	Yes	No	532,535	88,107,426

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm

31 Jan 25

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ:PROK) breached their fiduciary duties to

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

7 Jan 25

WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for

ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

26 Nov 24

WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for